Shanghai Kehua Bio-Engineering Co Ltd Asset Resilience Ratio
Shanghai Kehua Bio-Engineering Co Ltd asset resilience ratio. Shanghai Kehua Bio-Engineering Co Ltd (002022) has an Asset Resilience Ratio of 0.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Kehua Bio-Engineering Co Ltd (002022) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanghai Kehua Bio-Engineering Co Ltd (2002–2025)
Asset resilience ratio of Shanghai Kehua Bio-Engineering Co Ltd from 2002 to 2025. This chart shows how Shanghai Kehua Bio-Engineering Co Ltd's Asset Resilience Ratio has changed over time. Read Shanghai Kehua Bio-Engineering Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Kehua Bio-Engineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shanghai Kehua Bio-Engineering Co Ltd (002022) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥305.66K | 0.01% |
| Total Liquid Assets | CN¥305.66K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Kehua Bio-Engineering Co Ltd maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Kehua Bio-Engineering Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Kehua Bio-Engineering Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Shanghai Kehua Bio-Engineering Co Ltd Asset Resilience Ratio by Year (2002–2025)
Shanghai Kehua Bio-Engineering Co Ltd asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Shanghai Kehua Bio-Engineering Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.30% | CN¥60.36 Million ≈ $8.83 Million |
CN¥4.64 Billion ≈ $679.19 Million |
+1.29pp |
| 2024-12-31 | 0.01% | CN¥293.59K ≈ $42.96K |
CN¥5.24 Billion ≈ $766.21 Million |
-4.65pp |
| 2023-12-31 | 4.65% | CN¥316.77 Million ≈ $46.35 Million |
CN¥6.81 Billion ≈ $996.19 Million |
+4.63pp |
| 2018-12-31 | 0.03% | CN¥962.53K ≈ $140.85K |
CN¥3.50 Billion ≈ $512.71 Million |
+0.01pp |
| 2010-12-31 | 0.02% | CN¥234.08K ≈ $34.25K |
CN¥1.09 Billion ≈ $159.05 Million |
-0.02pp |
| 2009-12-31 | 0.04% | CN¥363.28K ≈ $53.16K |
CN¥925.84 Million ≈ $135.48 Million |
-0.28pp |
| 2006-12-31 | 0.32% | CN¥1.56 Million ≈ $228.10K |
CN¥484.49 Million ≈ $70.90 Million |
-4.11pp |
| 2002-12-31 | 4.43% | CN¥10.00 Million ≈ $1.46 Million |
CN¥225.50 Million ≈ $33.00 Million |
-- |
About Shanghai Kehua Bio-Engineering Co Ltd
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more